Hookipa Pharma Sells HBV and HIV Assets to Gilead

Reuters10-31
<a href="https://laohu8.com/S/HOOK">Hookipa Pharma</a> Sells HBV and HIV Assets to <a href="https://laohu8.com/S/GILD">Gilead</a>

HOOKIPA Pharma Inc. announced the completion of the sale of its assets related to the HB-400 program and certain assets of the HB-500 program to Gilead Sciences, Inc. The transaction includes assets involved in clinical development for hepatitis B and human immunodeficiency virus.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hookipa Pharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9565809-en) on October 31, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment